Blog Archives

Heart disease prediction by traditional risk factors as good as with an exhaustive genetic test

February 20, 2020 – Traditional cardiovascular risk factors often assessed in an annual physical, such as blood pressure, cholesterol levels, diabetes, and smoking status, may at least be as valuable in predicting who will develop coronary heart disease (CHD) as a sophisticated genetic test that surveys millions of different points in DNA,

Read more ›

Tags: , , , , , , , , , , , , , , , , , ,

Cholangiocarcinoma: Diabetes Drugs In DPP-4 Inhibitor Class Associated With Doubled Risk

Read more ›

Tags: , , , , , , , , , , , , , , , , , , , , ,

Heart attacks and stroke: The risk of DPP-4 anti-diabetes drugs

May 06, 2018 – In April 2016 the American Food and Drug Administration (FDA) took regulatory action by mandating label changes with new warnings about an increased risk of heart failure for  new diabetes medicines in the dipeptidyl peptidase-4 (DPP-4) inhibitor drug class, including Saxagliptin (Onglyza),

Read more ›

Tags: , , , , , , , , , , , , , , , ,

Diabetes is manageable if you know how

November 14, 2017 – Diabetes is manageable if you know how

Article by author Chloe Pearson.

Article top photo Jenny Hill at Unplash.

If you have diabetes, you already know that staying healthy is going to be a challenge: Keeping track of your blood sugar,

Read more ›

Tags: , , , ,

Diabetes: Is rhabdomyolysis associated with DPP-IV inhibitors?

October 15, 2017 – According to the quarterly safety report April – June 2017 by the American Food & Drug Administration (FDA), originating from the  FDA Adverse Event Reporting System (FAERS), the class of diabetes drugs referred to as dipeptidyl peptidase-4 inhibitors (DPP-IV inhibitors) may be associated with rhabdomyolysis,

Read more ›

Tags: , , , , , , , , , , , , , , , , , , , , , , , , ,

Is there a heightened risk of heart failure with diabetes medications containing saxagliptin and alogliptin?

April o5, 2016 – There have been indications that a heightened risk of heart failure may be associated with diabetes medications containing the pharmacologically active ingredients saxagliptin or alogliptin.  In the US, this includes  the FDA-approved drugs Saxagliptin (Onglyza), Saxagliptin/Metformin (Kombiglyze XR), Alogliptin (Nesina), Alogliptin/Metformin (Kazano), and Alogliptin/Pioglitazone (Oseni).

Read more ›

Tags: , , , , , , , , , ,


Diabetes-Arzneimittel mit dem Wirkstoff Rosiglitazon – Vorgesehene Sistierung der Zulassung in der Europäischen Union.

23. September 2010 – Das Arzneimittel-Institut der Schweiz (Swissmedic) hat heute folgende Mitteilung veröffentlicht:

23.9.10. – Swissmedic.  Die Arzneimittelbehörde der EU (EMEA) sieht vor, die Zulassung der Diabetes-Medikamente mit dem Wirkstoff Rosiglitazon zu suspendieren; sie werden dort in einigen Monaten nicht mehr erhältlich sein. Mit diesem Wirkstoff sind in der Schweiz die Präparate Avandia® und Avandamet® Tabletten zugelassen (Rosiglitazon bzw.

Read more ›

Tags: , , , , ,

European Medicines Agency (EMEA) recommends withdrawal of Benfluorex from the market in European Union

December 31, 2009 – The European Medicines Agency (EMEA) has recommended the withdrawal of all medicines containing Benfluorex in the European Union, because their risks, particularly the risk of heart valve disease, are greater than their benefits.

Doctors should stop prescribing Benfluorex-containing medicines and consider alternative treatments.

Read more ›

Tags: , , , ,

thasso: conditions

thasso: newest tweets

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Gene donors at high risk for cancer received feedback November 25, 2020
    Researchers at the Estonian Genome Center at the University of Tartu studied how people at high risk for breast, ovarian or prostate cancer responded to the feedback of genetic findings. Gene donors who chose to receive results appreciated being contacted and considered the information provided to be valuable. Authors find that knowing more about people's […]
  • Researchers reveal how genetic variations are linked to COVID-19 disease severity November 25, 2020
    Even as tens of thousands of Americans test positive for COVID-19 each day, physicians still aren't sure why some people experience mild to no symptoms while others become critically ill. New research led by Robert E. Gerszten, MD, Chief of the Division of Cardiovascular Medicine at Beth Israel Deaconess Medical Center (BIDMC) sheds new light […]
  • Study identifies new functions in the gene that causes Machado-Joseph disease November 25, 2020
    Ataxia is a minority disease with genetic origins, known for its neuromuscular alterations due to the selective loss of neurons in the cerebellum, the organ of our nervous systems which controls movement and balance. UB researchers have identified new functions in the ataxin 3 gene (ATXN3)–which causes Machado-Joseph disease, the most common type of ataxia– […]
  • BICRA gene provides answers to patients, doctors and scientists November 23, 2020
    Physicians and scientists are constantly on the lookout for new disease genes that can help them understand why patients have undiagnosed medical problems. Often the first clues come from genetic testing that reveals a change or mutation in a gene that they see in a child but not their parents. This is exactly what led […]
  • New targeted therapy blocks metabolism in brain cancer cells with genetic vulnerability November 23, 2020
    Researchers at The University of Texas MD Anderson Cancer Center have developed a novel targeted therapy, called POMHEX, which blocks critical metabolic pathways in cancer cells with specific genetic defects. Preclinical studies found the small-molecule enolase inhibitor to be effective in killing brain cancer cells that were missing ENO1, one of two genes encoding the […]
Top